Latest News about HALO
Recent news which mentions HALO
The 3 Best Biotech Stocks to Buy in Q2 2024
March 29, 2024
From InvestorPlace
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
March 13, 2024
From InvestorPlace
Breaking Down Halozyme Therapeutics: 7 Analysts Share Their Views
February 21, 2024
Tickers
HALO
From Benzinga
Earnings Scheduled For February 20, 2024
February 20, 2024
From Benzinga
Gates Ventures, Mayo Clinic Back Tiny Robot Created By $400M Apple Face ID Inventors To Treat Brain Disease
February 15, 2024
From Benzinga
Making Inception A Reality? Prophetic's $2000 AI Headband Promises To Let You Control Dreams
January 31, 2024
From Benzinga
Bristol Myers' Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients
January 29, 2024
From Benzinga
3 Biotech Stocks to Sell in January Before They Crash and Burn
January 25, 2024
From InvestorPlace
Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market Expansion
January 18, 2024
From Benzinga
Expert Outlook: Halozyme Therapeutics Through The Eyes Of 4 Analysts
January 18, 2024
Tickers
HALO
From Benzinga
Roche's One Of Largest Selling Cancer Drug Approved Under The Skin Injection Version In Europe
January 16, 2024
From Benzinga
4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond
January 16, 2024
From Motley Fool
Expert Outlook: Halozyme Therapeutics Through The Eyes Of 4 Analysts
December 26, 2023
Tickers
HALO
From Benzinga
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
November 09, 2023
From InvestorPlace
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
November 09, 2023
From InvestorPlace
3 Promising Biotech Stocks Flying Under the Radar
November 08, 2023
From InvestorPlace
Earnings Scheduled For November 6, 2023
November 06, 2023
From Benzinga
Millionaire Secrets: 3 Stocks to Turn $1,000 Into a Fortune
October 27, 2023
From InvestorPlace
Opdivo's Subcutaneous Formulation Shows Promise in Advanced Kidney Cancer: Bristol Myers Squibb's Latest Findings
October 19, 2023
From Benzinga
7 Sleeper Stocks That Should Be on Every Investor’s Radar This Fall
September 23, 2023
From InvestorPlace
Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations
July 28, 2023
From Benzinga
Halozyme's Subcutaneous Drug Delivery: Analysts Initiate With 'Buy' Rating, Say Enhanze Tech Targets $41.7B Market
July 24, 2023
Tickers
HALO
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.